Anti-VEGF therapy in retinopathy of prematurity
10.3980/j.issn.1672-5123.2020.11.11
- VernacularTitle:玻璃体腔注射抗VEGF药物治疗早产儿视网膜病变的研究进展
- Author:
Qin Peng
1
Author Information
1. 1Affiliated Eye Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China; 2Department of Ophthalmology, the People's Hospital of Zhangshu City, Zhangshu 331200, Jiangxi Province, China
- Publication Type:Review
- Keywords:
retinopathy of prematurity;
vascular endothelial growth factor;
anti-vascular endothelial growth factor agents
- From:
International Eye Science
2020;20(11):1894-1897
- CountryChina
- Language:Chinese
-
Abstract:
Retinopathy of prematurity(ROP)is an immature proliferative retinal vascular disease that may lead to permanent blindness in preterm infant. Retinal laser photocoagulation is used for ablation of peripheral retina and treatment of ROP, however, it is destructive. Especially for the cases with lesions in Zone I region, retinal laser photocoagulation may cause severe complications. Recently, studies have demonstrated that vascular endothelial growth factor(VEGF)plays a causal role in the pathogenesis of ROP, and intravitreal injection of anti-VEGF agents can not only effectively impede ROP progression, but also gain timing for revascularization of a vascular retinal region. This article reviews the treatment indications, drug selection, injection site, dosage recommendation, follow-up of efficacy and complications of intravitreal injection of anti-VEGF agents in the treatment of ROP.
- Full text:202011011.pdf
